ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
Pride month at ProQR is an opportunity to celebrate and thank all of the LGBT+ people in our communities, including our employees, scientists, and doctors that made our research possible.
… ProQR welcomes a new generation of scientists Throughout the … The visit began with general presentations about ProQR, our history, and Axiomer™ RNA editing technology, as … of our innovative laboratories in Leiden, including the R&D, CMC and Histology departments, and the practical work …
… ProQR Therapeutics Virtual R&D Event 2023 ProQR will host a virtual R&D event on Wednesday, March 29, … under “Events” in the “Investors & Media” section of ProQR’s website at www.proqr.com/events . The presentation is …
